Rebecca Liang

Reporter, The Block

· tracked since Apr 2026

Calls 1 1 Posts tracked · 0.0/day

Calls

7d 0

30d 0

90d 1

Best Calls

No live winners yet

Worst Calls

600276.SS long -16.3%

Most Mentioned

1801.HK ×1

600276.SS ×1

Recent Calls

600276.SS long 1 month ago

Win Rate 0% Long 1 Short 0

Win Rate

7d 0%

30d 0%

90d —

Average Return -16.3% Long Return -16.3% Short Return -

Average Return

7d -3.2%

30d -9.0%

90d —

Ticker

Side

Mentions

Opened

Entry

P&L

Thesis

Theme

Source

600276.SS Jiangsu ... Jiangsu Hengrui Med...

Long

Apr 27

$55.38

-16.3%

Long Innovent Biologics and Hengrui Medicine.

She recommends Innovent Biologics and Hengrui Medicine as top picks in the Chinese pharmaceutical sector. Innovent is a maturing biopharma transitioning to global level with a strong pipeline and deal-making capability. Hengrui is a traditional company successfully phasing out legacy products and replenishing with innovative drugs. Both have clinical catalysts and are positioned to benefit from China's growing dominance in global drug R&D.

Healthcare

YOUTUBE

Showing 1 of 1 picks · sorted by mentions